Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review
Suzanne A Ligthart1, Eric P Moll van Charante1, Willem A Van Gool2, Edo Richard2
1Department of General Practice, 2Department of Neurology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Background: Over the last decade, evidence has accumulated that vascular risk factors increase the risk of Alzheimer disease (AD). So far, few randomized controlled trials have focused on lowering the vascular risk profile to prevent or postpone cognitive decline or dementia.
Objective: To systematically perform a review of randomized controlled trials (RCTs) evaluating drug treatment effects for cardiovascular risk factors on the incidence of dementia or cognitive decline.
Selection criteria: RCTs studying the effect of treating hypertension, dyslipidemia, hyperhomocysteinemia, obesity, or diabetes mellitus (DM) on cognitive decline or dementia, with a minimum follow-up of 1 year in elderly populations.
Outcome measure: Cognitive decline or incident dementia.
Main results: In the identified studies, dementia was never the primary outcome. Statins (2 studies) and intensified control of type II DM (1 study) appear to have no effect on prevention of cognitive decline. Studies on treatment of obesity are lacking, and the results of lowering homocysteine (6 studies) are inconclusive. There is some evidence of a preventive effect of antihypertensive medication (6 studies), but results are inconsistent.
Conclusion: The evidence of a preventive treatment effect aimed at vascular risk factors on cognitive decline and dementia in later life is scarce and mostly based on secondary outcome parameters. Several important sources of bias such as differential dropout may importantly affect interpretation of trial results.
Keywords: cardiovascular risk factors, cognitive decline, dementia, prevention
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Readers of this article also read:
Haji SA, Sambhav K, Grover S, Chalam KV
Published Date: 19 December 2014
The "Pulse Time Index of Norm" highly correlates with the left ventricular mass index in patients with arterial hypertension
Posokhov IN, Kulikova NN, Starchenkova IV, Grigoricheva EA, Evdokimov VV, Orlov AV, Rogoza AN
Published Date: 19 March 2014
Curcumin and 5-Fluorouracil-loaded, folate- and transferrin-decorated polymeric magnetic nanoformulation: a synergistic cancer therapeutic approach, accelerated by magnetic hyperthermia
Balasubramanian S, Girija AR, Nagaoka Y, Iwai S, Suzuki M,
Kizhikkilot V, Yoshida Y, Maekawa T, Nair SD
Published Date: 9 January 2014
De Caterina AR, Harper AR, Cuculi F
Published Date: 19 July 2012
Effects of a 6-month exercise program pilot study on walking economy, peak physiological characteristics, and walking performance in patients with peripheral arterial disease
Crowther RG, Leicht AS, Spinks WL, Sangla K, Quigley F, Golledge J
Published Date: 17 April 2012
Katsuya Suzuki, Shigekazu Tsubaki, Masami Fujita, et al
Published Date: 3 November 2010
Hiroshi Kashimura, Kuniaki Ogasawara, Yoshitaka Kubo, et al
Published Date: 3 March 2010
Pawan D Patel, Rohit Bhuriya, Dipal D Patel, et al
Published Date: 5 August 2009
Ferruccio De Lorenzo, Marta Boffito, Sophie Collot-Teixeira, Brian Gazzard, John L McGregor, Kevin Shotliff, Han Xiao
Published Date: 26 March 2009